Search
AK119
go.drugbank.com/drugs/DB16423InvestigationalAK119 is a humanized anti-CD73 monoclonal antibody being investigated in the clinical trial NCT04516564 (A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects).
Olokizumab
go.drugbank.com/drugs/DB13127InvestigationalInterleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system. IL-6 pathway dysregulation is associated with ch...
Eflornithine
go.drugbank.com/drugs/DB06243ApprovedInvestigationalWithdrawnThis approval is based on positive results obtained from a multi-site, single-arm, externally controlled study of children with high-risk neuroblastoma, where a 52% reduction in the risk of relapse and
Capivasertib
go.drugbank.com/drugs/DB12218ApprovedInvestigationalThis approval is based on favorable results obtained from the CAPItello-291 trial, where the combination of capivasertib and [fulvestrant] reduced the risk of disease progression or death by 50% versus
Inebilizumab
go.drugbank.com/drugs/DB12530ApprovedInvestigationalInebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD.
Quizartinib
go.drugbank.com/drugs/DB12874ApprovedInvestigational[L47436] The FDA approval was based on positive results from the QuANTUM-First trial for FLT3-ITD positive AML, where quizartinib combined with standard cytarabine and anthracycline induction and standard
Synonyms: N-(5-(1,1-Dimethylethyl)isoxazol-3-yl)-N'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)ureaPiclidenoson
go.drugbank.com/drugs/DB05511InvestigationalCF 101 (known generically as IB-MECA) is an anti-inflammatory drug for rheumatoid arthritis patients. Its novel mechanism of action relies on antagonism of adenoside A3 receptors. CF101 is supplied as an oral drug and has an excellent sa...
Rozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigationalRozanolixizumab-noli is available under the brand name RYSTIGGO and was developed by UCB.
ST-36
go.drugbank.com/drugs/DB17275ExperimentalST-36 is a cell-penetrating dominant-negative form of activating transcription factor 5. In 2017, it received orphan drug designation by the FDA for the treatment of glioma.[L47341]